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INTRODUCTION 
 Thyroid carcinoma is a fascinating tumor because of the diversity in the 
tumor presentation and behaviour.  It is a relatively rare tumor, though it is the 
most common endocrine malignancy.  The incidence of thyroid malignancy is 
rising rapidly.  This may be due to the large number of incidentalomas found 
during routine head and neck evaluations and better investigatory procedures 
available now. 
 Thyroid cancer is a heterogenous disease that affects all age groups.  
The tumors are found to be more aggressive in the elderly.  Controversy still 
exists over the treatment of this cancer because of the long term survival of 
patients with differentiated thyroid cancers irrespective of the type or extent of 
treatment.  A high index of suspicion is required for the diagnosis of these 
cancers. 
 Undifferentiated thyroid cancers continue to have a dismal prognosis.  
Anaplastic thyroid carcinoma remains one of the most difficult human 
malignancies to treat and is highly lethal. 
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 Medullary thyroid cancer is one of the best characterized solid 
malignancies.  The genetic abnormalities in these patients can be diagnosed 
accurately.  This can be used to detect and treat patients with familial gene 
mutations at an earlier stage. 
 The knowledge base about thyroid malignancies is continuously 
evolving and may lead to better treatment options in the future. 
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AIM OF STUDY 
1. To study the epidemiology of thyroid cancers. 
2. To study the prevalence of the different types of thyroid cancers 
3. To analyse the clinical presentations of malignant thyroid neoplasms 
4. To evaluate the various modalities for treatment of thyroid cancer 
5. To study the role of neck dissections in thyroid cancers. 
6. To analyse the role of TSH suppressive treatment with thyroxine for 
malignancies of thyroid. 
7. To evaluate the outcome of patients treated for thyroid malignancies. 
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REVIEW OF LITERATURE 
HISTORICAL BACKGROUND 
¾ The word Goitre is derived from the Latin word ‘Guttur’ which means 
throat.  Goitres have been recognized since 2700 BC (14). 
¾ The name thyroid is derived from the Greek word thyreoeides meaning 
shield shaped. This name was given by Thomas Wharton in his work 
‘Adenographia’ in 1656 (14). 
¾ Iodine – rich seaweed was used for treatment of goiter. 
¾ First account of thyroid surgery was by Roger Frugardi in 1170 (14). 
¾ Two surgeons contributed greatly to the advancement of thyroid surgeries. 
They were Emil Theoder Kocher (1841-1917) and C.A. Theodor Billroth 
(1829-1894). 
¾ In recognition ‘For his work on physiology, pathology and surgery of the 
thyroid gland’ Kocher was awarded the Nobel Prize in 1909. 
¾ Felix Simon recognized that myxedema is due to loss of thyroid function. 
¾ Myxedema was effectively treated first by George Murray in 1891. 
¾ Oral therapy for hypothyroidism was later introduced by Edward Fox. 
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¾ Edward Kendall isolated the bioactive material from the thyroid in 1914. 
¾ William Halstead revolutionized surgical treatment and education and 
contributed greatly to the operative treatments of the thyroid gland. 
EMBRYOLOGY 
 The thyroid gland arises as a midline diverticulum from the floor of the 
primitive foregut around the 3rd week of gestation (14).  Endodermal cells in 
this region thicken to form the medial thyroid anlage.  This descends in the 
neck anterior to the hyoid bone and larynx.  The original attachment to the 
pharynx is in the oral cavity at the foramen cecum.  The anlage remains 
connected to the foramen cecum by an epithelial lined tube known as the 
thyroglossal duct.  The epithelium of the anlage gives rise to the thyroid 
follicular cells.  Lateral anlages arise on both sides from the fourth branchial 
pouch and fuse with the median anlage at fifth week of gestation.  The lateral 
anlages are neuroectodermal in origin.  They form the parafollicular or ‘C’ 
cells.  Thyroid follicles appear at 8 weeks of gestation. Colloid formation 
begins by the 11th week of gestation. 
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SURGICAL ANATOMY 
 The normal thyroid gland consists of right and left lobes that are joined 
to each other by the isthmus.  A pyramidal lobe which is found in about 50% of 
people represents the distal end of the thyroglossal duct.  The gland is brown in 
colour and firm in consistency.  In weighs approximately 20 g (14).  The 
thyroid lobe extends from mid-thyroid cartilage superiorly and lies adjacent to 
the carotid sheath and sternomastoid muscles laterally.  The isthmus lies in 
front of the second and third tracheal rings.  The thyroid gland has two 
capsules; a true capsule which is the peripheral condensation of the connective 
tissue of the gland and a false capsule which is formed by the pretracheal layer 
of deep cervical fascia.  This false capsule is thickened posteriorly where it 
forms the suspensory ligament of berry which is attached to the cricoid 
cartilage (7). 
ARTERIAL SUPPLY 
 The thyroid is a highly vascular organ.  It is supplied by four main 
arteries two superior and two inferior thyroid arteries. 
SUPERIOR THYROID ARTERIES 
The superior thyroid artery is the first branch of the external carotid 
artery.  It descends medially on the surface of the inferior constrictor muscle 
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and enters the superior pole of the thyroid gland before which it divides into 
anterior and posterior branches. 
INFERIOR THYROID ARTERIES 
 The inferior thyroid artery is a branch of the thyroicervical trunk. It 
passes behind the carotid sheath and in front of the vertebral vessels as it 
travels upwards.  It then turns medially and enters the thyroid gland posteriorly. 
THYROIDEA IMA ARTERY 
 It arises directly from the aorta or innominate artery in 1-4% of 
individuals (14).  It enters the lower part of the isthmus. 
ACCESSORY THYROID ARTERIES 
These arise from the tracheal and esophageal arteries and supply the 
thyroid. 
VENOUS DRAINAGE 
 The venous drainage of the thyroid gland is via multiple small surface 
veins which coalesce to form 3 sets of veins: the superior, middle and inferior 
thyroid veins.  The superior thyroid veins accompany the superior thyroid 
arteries and drain into the internal jugular vein.  The middle thyroid veins are 
least consistent-they course immediately laterally into the internal jugular vein.  
The inferior thyroid veins are usually 2 to 3 in number and drain into the 
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branchiocephalic veins.  A fourth thyroid vein (of Kocher) may emerge 
between the middle and inferior veins and drain into the internal jugular vein. 
LYMPHATIC SYSTEM 
 Lymphatic channels are present beneath the capsule of the gland and 
communicate between the lobes through the isthmus.  The lymphatics drain 
into the regional lymph nodes which are the pretracheal, paratracheal, 
tracheobronchial nodes, mediastinal nodes in anterior and superior position,  
upper, middle and lower jugular nodes, retropharyngeal and esophageal nodes. 
NERVES 
 The sympathetic innervation is from the superior and middle cervical 
sympathetic ganglia.  The sympathetics are vasomotor in action.  
Parasympathetics are derived from the vagus nerve and reach the gland via 
branches of the laryngeal nerves. 
RELATIONSHIP OF RECURRENT LARYNGEAL NERVE 
 The left recurrent laryngeal nerve arises from the vagus where it croses 
the aortic arch, loops around the ligamentum arteriosum and ascends medially 
in the neck within the tracheoesophageal groove.  On the right side, the nerve 
arises from the vagus at its crossing with the right subclavian artery.  Its course 
is more oblique than the left. 
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 The nerve may be non recurrent in 0.5-1% of patients.  This is more 
common on the right (14). 
 The recurrent laryngeal nerves may branch or pass anterior or posterior 
or interdigitate with branches of inferior thyroid artery.  They enter the larynx 
on the caudal border of the cricothyroid muscle.  Here the nerves are in close 
proximity to the superior parathyroid, the inferior thyroid artery and the most 
posterior aspect of the thyroid.  It is essential to identify the entire course of the 
nerves in the neck during thyroid surgeries. 
 The recurrent laryngeal nerve supplies all the intrinsic muscles of the 
larynx except the cricothyroid.  Damage to the nerve causes ipsilateral vocal 
cord paralysis. 
RELATIONSHIP OF THE SUPERIOR LARYNGEAL NERVE 
 The superior laryngeal nerves arise from the vagus nerves.  They 
originate at the base of the skull and travel along the internal carotid artery.  
They divide into two branches at the level of the hyoid bone the internal and 
external laryngeal nerve.  The external laryngeal nerve descends alongside the 
superior thyroid vessels before supplying the cricothyroid muscle.  Injury to the 
nerve during surgery causes alteration in the pitch of the voice. 
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PHYSIOLOGY OF THE THYROID GLAND 
 Thyroid hormones affect almost every system in the body.  They 
increase oxygen consumption, basal metabolic rate and heat production in 
various tissues.  They help to regulate the lipid and carbohydrate metabolism.  
They are necessary for normal growth and maturation. 
 The main hormones secreted by the thyroid are thyroxine (T4) and 
triiodothyronine (T3). T3 is also formed by deiodination of T4 in peripheral 
tissues. 
IODINE METABOLISM 
 Iodine is the mineral required for thyroid hormone synthesis.  The 
average daily requirement is 100-150 micrograms (6).  The thyroid is the 
storage site of greater than 90% of the body’s iodine content.  Iodide is actively 
transported into the thyroid follicular cells by an ATP dependent process. 
Thyroid Hormone synthesis 
The thyroid cells have 3 functions 
1. They collect and transport iodine 
2. They synthesize thyroglobulin and secrete it into colloid 
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3. They remove the thyroid hormones from thyroglobulin and secrete them 
into the circulation 
In the thyroid gland, iodide is oxidized to iodine and bound to 3 
positions of tyrosine residues that are part of the thyroglobulin molecule in the 
colloid.  Thyroglobulin is synthesized in the thyroid cells and secreted into the 
colloid by exocytosis of granules that also contain thyroid peroxidase.  This 
enzyme catalyzes the oxidation of iodide and its binding.  The thyroid 
hormones remain a part of the thyroglobulin till they are secreted.  When they 
are secreted, colloid is ingested by the thyroid cells, the peptide bonds are 
hydrolyzed, and free T4 and T3 are released into the capillaries. 
In the process of hormone synthesis, monoiodotyrosine (MIT) is 
produced first.  It is next iodinated in the fifth position to form diiodotyrosine 
(DIT).  Two molecules of DIT undergo oxidative condensation to form T4.  T3 
is formed by condensation of DIT with MIT.  The average distribution of these 
compounds in the normal thyroid is 23% MIT, 33% DIT, 35% T4 and 7% T3 
(6). 
SECRETION 
 The human thyroid secretes 80 μg of T4, 4 μg of T3 and 2 μg of RT3 
per day.  MIT and DIT are not secreted.  The thyroid cells ingest colloid by 
endocytosis.  In the cells, the globules of colloid merge with lysosomes.  The 
peptide bonds between the iodinated residues and thyroglobulin are broken by 
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the proteases in the lysosomes.  T4 and T3 are liberated and are released into 
the circulation.  The iodine associated with the MIT and DIT is liberated by the 
deiodinase enzyme and is reutilized for thyroid hormone synthesis. 
TRANSPORT AND METABOLISM 
 The normal total plasma T4 level is approximately 8 μg/dl and the 
plasma T3 level is approximately 0.15 μg/dl.  Large amounts of both are bound 
to plasma proteins. 
 The plasma proteins that bind thyroid hormones are albumin, 
transthyretin, and thyroxine – binding globulin (TBG). 
 99.98% of T4 is plasma is protein bound.  The free T4 level is about 2 
ng/dl.  The half life of T4 is 6-7 days (6). 
 99.8% of T3 is protein bound in plasma.  The free T3 level is 0.3 ng/dl.  
It has a shorter half life than T4 (6). 
 The free thyroid hormones in plasma are in equilibrium with the protein 
bound thyroid hormones in plasma and in tissues. 
 It is the free thyroid hormones in plasma that are physiologically active.  
It is this fraction that inhibits pituitary secretion of TSH. 
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METABOLISM OF THYROID HORMONES 
 T4 and T3 are deiodinated in the liver, the kidneys and other tissues.  
One third of circulating T4 is normally converted to T3 and 45% is converted 
to RT3.  In the liver, T4 & T3 are conjugated to form sulphonates and 
glucoronides.  These conjugates enter the bile and pass into the intestine. The 
thyroid conjugates are hydrolysed, some are resorbed and some are exerted in 
the stool. 
REGULATION OF THYROID SECRETION 
 Pituitary TSH is the primary hormone controlling the thyroid gland 
function.  TRH is secreted by the hypothalamus.  This in turn increases 
secretion of TSH. Circulating free T3 and T4 inhibit TSH by a negative 
feedback mechanism. 
PATHOLOGY 
 Malignant thyroid neoplasms are classified as follows (16): 
Primary epithelial tumors: 
A) Tumours of follicular cells 
Well differentiated 
Papillary 
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Follicular 
Poorly Differentiated 
Insular 
Others 
Undifferentiated – Anaplalstic 
B) Tumors of C cells 
Medullary carcinoma 
C) Tumors of follicular and C cells 
Mixed medullary follicular carcinoma 
Primary Non epithelial Tumors: 
Malignant Lymphomas 
Sarcomas 
Others 
Secondary Tumors, Metastatic 
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Thyroid Oncogenesis 
 The development of thyroid neoplasia includes two important processes: 
Mutated protooncogenes which result in altered protein production thus an 
acceleration in growth and alternations in tumor suppressor genes that cause 
unregulated cell growth (13). 
Oncogene Activators 
1. ras Gene Family – This gene family encodes signal transduction G 
proteins.  Mutational activation of this oncogene causes production of 
inactive form of enzymes that degrade proteins.  Thus continuous 
protein accumalation is allowed. 40% of thyroid tumors may have one 
of the three ras gene point mutations (H- ras, K-ras or N-ras). K-ras 
mutations are more frequent in radiation-induced papillary cancers.  
Patients in iodine sufficient areas have a higher incidence of ras 
mutations. 
2. RET protooncogene – This encodes for a tyrosine kinase receptor on the 
cell membrane.  It is involved in the differentiation of neuronal cells.  
Mutation of this gene is associated with the development of medullary 
carcinoma of thyroid, papillary carcinoma of thyroid and predilection of 
the cancer for distant metastasis.  There is increased prevalence in 
patients who have had radiation exposure. 
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3. Tyrosine kinase Receptors – Activations of these receptors leads to a 
cascade of events which through phosphorylation activate multiple 
pathways with a variety of metabolic results.  Three different tyrosine 
kinase receptor groups (RET, trk, met) have been implicated in the 
development of thyroid cancer. 
Tumor suppressor Genes: p53 
 This gene encodes a phosphoprotein that inhibits several genes 
responsible for normal cell growth and differentiation.  Mutations of p53 are 
found in the late stage of tumor growth and spread and in the more poorly 
differentiated anaplastic thyroid cancer. 
Papillary Carcinoma 
 It is the most common thyroid malignancy.  It accounts for 80-85% of 
all thyroid cancers (5).  There is a 2:1 female preponderance in the incidence of 
papillary carcinoma.  Mean age at presentation is 30-40 years (14). 
Macroscopic Pathology 
 Papillary carcinomas may be solitary or multifocal lesions within the 
thyroid.  Cystic change, calcification and ossification may be found in the 
tumor.  Tumors may appear well circumscribed and capsulated or may infiltrate 
adjacent parenchyma.  Microcarcinomas are papillary thyroid carcinomas 
smaller than 1 cm. 
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Microscopic Pathology 
 Papillary carcinomas may have branching papillae with a fibro vascular 
stalk covered by epithelium.  The cells are cuboidal with pale, abundant 
cytoplasm; crowded nuclei and intranuclear cytoplasmic inclusions.  These are 
the ‘Orphan Annie nuclei.’  Nuclear pseudo inclusions and nuclear grooves are 
characteristic features.  Concentrically calcified structures termed psammoma 
bodies may be present within the lesion. 
 Histological variants of papillary carcinoma are: mixed papillary and 
follicular, follicular, tall cell, insular, columnar, diffuse sclerosing, clear cell, 
trabercular and poorly differentiated types (14). 
Follicular Carcinoma: 
 This constitutes 5-10% of all thyroid malignancies (5).  Women have a 
higher incidence of this cancer, with female: male ratio of 3:1.  Mean age of 
presentation is 50 years (14). 
Macroscopic Pathology 
 These are single nodules that may be well circumscribed or infiltrative.  
Large lesions may penetrate capsule and infiltrate into the adjacent neck.   
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Microscopic Pathology 
Follicular carcinoma can only be diagnosed in the presence of capsular, 
lymphatic or vascular invasion. 
 Using these criteria 2 types of follicular carcinoma are described (14) 
a. Minimally invasive carcinoma where microscopic examination is 
required to demonstrate lymphavascular and capsular invasion and 
b. widely invasive carcinoma where gross invasion is seen. 
Follicular carcinoma cannot be diagnosed by an FNAC. 
Hurthle cell carcinoma 
 It accounts for 3% of the thyroid cancers (14).  It is considered a subtype 
of follicular thyroid cancer.  It cannot be diagnosed by FNAC.  30% of hurtle 
cell carcinomas are multifocal and bilateral.  Only 5% of these tumors take up 
radioactive iodine.  20% of the tumors metastasise in 10 years (14). 
Microscopic Pathology 
 The tumor cells arise from the oxyphillic cells of the thyroid.  The 
tumors contain sheets of eosinophillic cells packed with mitochondria. 
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Medullary Carcinoma 
 5% of all thyroid malignancies are medullary carcinomas of thyroid. 
They arise from the parafollicular or ‘C’ cells of thyroid. 
Microscopic Pathology 
They may arise as a solitary nodule which is commonly seen in the 
sporadic type or may be multicentric and bilateral which are common in 
familial cases. 
Microscopic Pathology 
 They are composed of polygonal to spindle shaped cells which may 
form nests, trabeculae and even follicles.  Acellular amyloid deposits derived 
from altered calcitonin molecules are charactertic findings (17). 
 Various patterns seen are: glandular, solid, spindle cell, oncocytic, clear 
cell, papillary, small cell and giant cell (5). 
Types of medullary carcinoma are (5) 
1. Sporadic 
2. Familial 
3. MEN 2A 
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4. MEN 2A with cutaneous lichen amyloidosis 
5. MEN 2A or familial medullary thyroid cancers with Hirshprung’s 
disease 
6. MEN 2B 
These tumors secrete calcitonin, carcinoembryonic antigen (CEA), 
calcitonin gene-related peptide, histaminadases, prostaglandins E2 and F2 and 
serotonin. 
Anaplastic carcinoma 
It is the most aggressive of thyroid malignancies.  This accounts for  
< 5% of all thyroid cancers.  Women are more commonly affected.  Most of the 
tumors present in the 7th and 8th decades of life.  The mean age of presentation 
is 65 years. 
Macroscopic Pathology 
 These tumors are firm and whitish in appearance. 
Microscopic Pathology 
Three histological patterns are seen (12): 
1. Large, pleomorphic giant cells 
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2. Spindle cells with a sacromatous appearance 
3. Small anaplastic cells resembling those seen in small cell carcinomas 
arising in other sites. 
Lymphoma 
 Lymphomas account for less than 1% of thyroid malignancies (15).  
They are mostly of the non-Hodgkin’s B cell type.  Most lymphomas develop 
in patients with Hashimoto’s thyroiditis. 
Metastatic Carcinoma 
 The thyroid gland is a rare site of metastasis.  The primary tumors 
usually are from the kidney, breast, lung and melanoma. 
EPIDEMIOLOGY 
 Thyroid cancer is the most common endocrine malignancy.  It accounts 
for 91.2% of the total new endocrine cancers and 56.5% of deaths due to 
endocrine cancers in the year 2002 (5).  The difference between the total 
number of cases of all endocrine cancers arising in the thyroid and total 
proportion of endocrine cancer deaths indicates that it is an indolent disease 
and is associated with long term survival. 
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Well differentiated cancer has a 2.5:1 female preponderance (4).  The 
median age at diagnosis is earlier in women than men for both papillary and 
follicular cancer. 
ETIOLOGY AND RISK FACTORS 
1. Radiation 
 Low dose therapeutic radiation of about 6.5 cGy – 1500 cGy was used 
to treat conditions like tinea capitis, thymic enlargement, enlarged tonsils and 
adenoids, acne vulgaris, hemangioma and scrofula in the past.  Radiation of 
about 4000 cGy is used to treat Hodgkin’s disease.  It is now known that 
exposure to low dose ionizing radiation to the thyroid gland causes increased 
risk of development of thyroid malignancy.  Most of these are papillary 
carcinoma of thyroid.  The risk is maximum 20-30 years after exposure, but 
patients require lifelong monitoring.  Over 9000 cGy the risk declines as the 
gland is sterilized. 
2. Iodine 
 Papillary carcinoma of thyroid may be common in areas with high 
iodine content in diet.  Follicular neoplasia is seen in regions having high 
incidence of goiter (iodine deficient areas.) 
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3. Heredity 
 Medullary carcinoma is inherited in an autosomal dominant form in 
20% of cases.  Other conditions associated with thyroid cancers are Gardner’s 
syndrome, Familial Polyposis and Cowden’s syndrome. 
Other risks factors are: 
1. Hashimoto’s thyroiditis 
2. Familial forms of papillary and follicular carcinoma 
Factors predisposing to thyroid cancer and types associated are: 
TSH   - Papillary 
Low dose radiation - Papillary 
Iodine deficiency - Follicular 
Iodine abundance - Papillary 
Genetic   - Medullary 
Thyroiditis  - Lymphoma 
Preexisting goiter / - Anaplastic 
neoplasia 
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Clinical Features (15) 
Histological features that suggest malignancy are: 
1. Young (<20 years) or old (>70 years) age 
2. Male sex 
3. A history of external neck radiation during childhood or adolescence 
4. Recent changes in speaking, breathing or swallowing. 
5. Family history of thyroid cancer or multiple endocrine neoplasia (MEN) 
type 2 
6. Rapid expansion of an existing nodule 
7. History of pain in a thyroid nodule 
The findings on physical examination which may indicate malignancy 
are 
1. Firm consistency of nodule 
2. Irregular shape 
3. Fixity to underlying or overlying tissues 
4. Significant regional lymphadenopathy 
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5. Features of Horner’s syndrome 
6. Vocal cord paralysis seen on indirect laryngoscopy. 
The above clinical features should increase the suspicion of a thyroid 
malignancy.  Confirmation of the diagnosis requires investigations. 
INVESTIGATIONS 
1. Fine Needle Aspiration Cytology (FNAC) 
FNAC was popularized in the 1960s by Einhorn and Frazen at the 
Karolinsta Institute, Stockholm.  It is an extremely sensitive and cost effective 
method of detecting thyroid malignancies.  The accuracy of FNAC ranges from 
70% to 97% (5). 
A variety of molecular markers have been tried in FNAC specimens to 
improve the yield of malignancy. These include telomerase activity, presence 
of loss of hetero zygosity by polymerase chain reaction based microsatellite 
analysis, patterns of protein expression by immunocytochemical analysis. 
False positive results for malignancy occur in 3-6% of FNAC specimens 
(5). 
False negative results occur in 1-6% of cases (5). 
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The results of FNAC can be classified as follows (5): 
Result    : Percentage of samples 
Benign    : 53-90% 
Malignant    : 1-10% 
Suspicious or indeterminate : 5-23% 
Insufficient sampling  : 15-20% 
Advantages of FNAC 
1. Preoperative diagnosis of malignancy is obtained which determines the 
type of surgery to be performed. 
2. It reduces the number of patients with benign nodules subjected to 
diagnostic thyroid lobectomies 
3. It is possible to diagnose lymphoma and anaplastic carcinoma by 
FNAC.  Unnecessary surgery is avoided in these patients. 
4. It has a high degree of sensitivity, specificity and accuracy at a low cost 
and can be done with minimum morbidity 
5. A diagnosis of malignancy on FNAC will prompt immediate treatment 
for the patient. 
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Disadvantages of FNAC 
1. Highly experienced pathologist is required for interpretation of the 
FNAC specimen. 
2. The malignant potential of follicular neoplasms cannot be determined on 
FNAC as it requires the demonstration of capsular and vascular 
invasion. 
3. It is less reliable in patients with history of head and neck irradiation or 
a family history of thyroid cancer because of higher likelihood of 
multifocal lesions 
2. Ultrasound of the neck 
 This is used to distinguish solid from cystic nodules, for detecting non-
palpable thyroid nodules, for identifying adjacent lymphadenopathy.  It proves 
as a noninvasive and inexpensive method of following the size of benign 
nodules.  USG guided FNAC can be done which may increase yield of FNAC 
as it enables the radiologist to take the sample from the solid areas of the 
nodule.  Pure cystic lesions which are 4 cm in size or larger have a 7% chance 
of malignancy.  Mixed solid and cystic lesions are malignant in 12% of cases 
while 21% of solid lesions are found at surgery to harbour malignancy (14). 
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3. Core Needle Biopsy / Trucut Biopsy 
 The indications for this are: 
1. Suspected anaplastic carcinoma of thyroid or lymphoma of thyroid 
2. Inoperable lesions 
4. Thyroid Scanning 
 The agents used for thyroid scanning are 123I, 131I and Technitium 99 m 
per technetate. 
 The thyroid scan can be used to differentiate between functioning and 
non functioning thyroid nodules.  15-20% of patients with cold nodules and       
< 5% of patients with hot or warm nodules have thyroid cancer (14). Thyroid 
scanning is currently recommended in the assessment of thyroid nodules only 
in patients who have follicular thyroid nodules on FNAC and a suppressed 
TSH (14). 
5. CT scan & MRI 
 These are unnecessary for routine evaluation of thyroid tumors. 
Indications for use are: large lesions, fixed lesions or substernal tumors.  
Invasion to adjacent organs can be diagnosed with these tests. 
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6. Blood Tests 
a. Thyroid function tests (T3, T4, TSH): This is used to determine the 
functional status of the thyroid gland. 
b. Thyroglobulin – It is used for monitoring patients with differentiated thyroid 
cancer for recurrence, especially after total thyroidectomy and radioactive 
iodine ablation. 
It can be elevated in various benign diseases of the thyroid like thyroiditis, 
Grave’s disease, toxic multinodular goiter 
c. Serum calcitonin levels can be measured in medullary carcinoma thyroid 
7. Position Emission Tomography (PET) Scan 
 18-FDG-PET Scan is used for localizing recurrent differentiated and 
poorly differentiated thyroid cancer especially if serum thyroglobulin is 
elevated and 131I whole body scan is negative. 
 PET identifies the source of thyroglobulin production in 50-80% of 
patients. 
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Management of Nodular Goitre (16) 
 
Thyroid Swelling 
 
 
Ultrasound Neck 
 
Multiple nodules        Single nodule 
            
T3, T4, TSH        Solid         Cystic 
 
 
Subtotal/Near total     FNAC 
Thyroidectomy   
 
Insufficient Benign   Malignant        Suspicious 
   Sample (15%)  (75%)     (5%)   (20%) 
 
 
  Repeat FNAC  Local Symptoms  Total  Operative 
               thyroidectomy Exploration 
Diagnostic Nondiagnostic Clinical         Consider   
   (50%)        (50%) followup hemithyroidectomy  Frozen Section 
 
  Ultrasound       Diagnostic for cancer 
  guided FNAC 
 
 
Diagnostic  Nondiagnostic           Stop with       Total 
   (90%)       (10%)     hemithyroidectomy thyroidectomy 
 
 
       Low risk  High risk 
 
 
      Follow up  Surgery 
 
 
      Single    Multiple 
 
 
     >2 cm/complex/   If asymptomatic, simple, 
                     symptomatic              none > 2 cm 
 
 
         FNAC              Observation 
 
   
Clear, Negative cytology  If bloody/ 
      LDH level increased/ 
      cyst recurs/residual mass/ 
       Observation   cell cytology positive 
     & repeat USG 
      after 6 months     
       Surgery 
 
No 
Yes
No 
Yes
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STAGING OF THYROID CANCER 
There are many scoring and staging systems for thyroid cancers.  
TNM clinical classification is the universally accepted system (5) 
Tx - Primary tumor cannot be assessed 
To - No evidence of primary tumor 
T1 - Tumor  ≤ 2 cm confined to the thyroid 
T2 - Tumor > 2 cm and < 4 cm confined to the thyroid 
T3 - Tumor > 4 cm confined to the thyroid or 
  Tumor of any size with minimal extrathyroid extension 
T4a - Tumor of any size with extra thyroid extension to subcutaneous  
soft tissues, larynx, trachea, esophagus or recurrent larygreal 
nerve or Intra thyroidal anaplastic carcinoma 
T4b - Tumor invading prevertebral fascia or encasing carotid artery or  
mediastinal vessels or Extrathyroidal anaplastic carcinoma 
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Regional lymph nodes (N) (Central compartment, lateral cervical and upper 
mediastinal) 
Nx - Regional lymph nodes cannot be assessed 
No - No regional lymph node metastasis 
N1 - Regional lymph node metastasis 
N1a - Metastasis to level VI (pretracheal, paratracheal and   
                       prelaryngeal) lymph nodes. 
N1b - Metastasis to unilateral, bilateral or contralateral cervical or  
                      superior mediatinal lymph nodes 
Distant Metastasis (M) 
Mx - Distant metastasis cannot be assessed 
Mo - No distant metastasis 
M1 - Distant metastasis 
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Stage Groupings 
Papillary and follicular carcinoma 
Under 45 years of age 
Stage I Any T  Any N Mo 
Stage II Any T  Any N M1 
45 years of age and over 
Stage I T1NoMo 
Stage II T2NoMo 
Stage III T3NoMo 
Stage III T1N1aMo 
  T2N1aMo 
  T3N1aMo 
Stage IV T4aNoMo 
  T4aN1aMo 
  T2N1bMo 
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  T3N1bMo 
  T4aN1bMo 
Stage IVB T4b any N Mo 
Stage IVC anyT any N M1 
Medullary Carcinoma 
Stage I T1No Mo 
Stage II T2No Mo 
  T3No Mo 
Stage III T1No Mo 
  T2N1aMo 
  T3N1aMo 
Stage IVA T4aNoMo 
  T4aN1aMo 
  T1N1bMo 
  T2N1bMo 
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  T3N1bMo 
  T4aN1bMo 
Stage IVB T4b any N Mo 
Stage IVC any T any N M1 
Anaplastic Carcinoma 
Stage IVA T4a any N Mo 
Stage IVB T4b any N Mo 
Stage IVC any T any N M1 
The other prognostic classification systems used for well differentiated thyroid 
cancers are described below (5): 
AGES Scale: The criteria included are: 
Age, Grade of tumor, Extent, Size of tumor 
AMES Scale: The following factors are included here: 
Age, Metastasis, Extent, Size of tumor 
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EORTC criteria: European organization for Research and treatment of cancer 
published the first prognostic scoring system for thyroid malignancies.  It 
includes the following: 
Age, Sex, Cell type, Extrathyroidal invasion, Metastases 
DAMES Criteria are: DNA ploidy, Age, Metastases, Size. 
MACIS SCALE: This takes into account the following factors: 
Metastases, Age, Completeness of resection, Invasion, Size. 
Ohio State Criteria – This includes the following: 
Size, cervical metastases, multiplicity, invasion, distant metastases. 
NTCTS Criteria (National Thyroid Cancer Treatment Cooperative Study) – 
The factors taken into account are: Size, multifocality, invasion, differentiation, 
cervical metastases, extracervical metastases. 
Sloan – Kettering Criteria – These are: 
 Age, histology, size, extension, metastases. 
Degroot and associates have classified thyroid cancers as follows to 
determine prognosis: class I (intrathyroidal) Class II (certival nodal) Class III 
(extrathyroidal invasion, Class IV (distant metastases). 
 
52
 These prognosic classification systems are used to divide patients with 
thyroid cancer into the low-risk and high-risk groups.  Such a division makes it 
possible to counsel patients and help guide decision making about the intensity 
of postoperative tumor surveillance and management. 
TREATMENT 
A. Surgical Treatment of thyroid carcinoma 
 The goal of surgery is to remove all the malignant neoplastic tissue in 
the neck.  The extent of surgery appropriate for thyroid malignancy depends on 
the histologic diagnosis, the size of the original lesion, the presence of distant 
metastasis, the patient’s age and the risk group category. 
The advantages of total thyroidectomy for well differentiated thyroid 
carcinoma are (5): 
1. Higher survival rate for lesions > 1.5 cm in diameter 
2. Lowest recurrence rate in all patients 
3. Prevention of recurrence in the contralateral lobe 
4. Reduction of the risk of developing pulmonary metastasis 
5. Can be performed with the same morbidity and mortality as 
hemithyroidectomy 
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6. Improved sensitivity of serum thyroglobulin as a marker for persistent or 
recurrent disease 
7. Radioactive iodine can be used to detect and treat persistent or recurrent 
disease 
8. Reduces possibility of residual tumor in contralateral lobe undergoing 
transformation to anaplastic carcinoma 
MANAGEMENT OF THE PRIMARY TUMOR 
Papillary Carcinoma 
 When patients are found to have micro papillary thyroid carcinoma in a 
specimen removed for other reasons, unilateral hemi thyroidectomy is 
sufficient as long as there is no extra thyroidal invasion. 
 In all other cases, total or near total thyroidecomy is the procedure of 
choice. 
Follicular Carcinoma 
 Patients who have FNAC diagnosis of follicular neoplasm should 
undergo a hemithyroidectomy and the specimen is to be sent for frozen section. 
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 For extremely low risk patients ie < 2 cm lesion with only capsular 
invasion ipsilateral hemithyroidectomy may be sufficient (16).  For all other 
cases, total thyroidectomy should be performed. 
Hurthle Cell Carcinoma 
 Total thyroidectomy with central compartment dissection is the 
procedure of choice for these patients 
Medullary Carcinoma 
 The recommended surgery for medullary carcinoma is total 
thyroidectomy with central compartment dissection.  Pheochromecytoma 
should be operated on first if present. 
Anaplastic Carcinoma 
 Prognosis for this cancer is very poor.  If the carcinoma presents as a 
resectable mass, total thyroidectomy may lead to a small improvement in 
survival especially in younger patients.  For patients with impending airway 
obstruction, isthmectomy should be done.  In the presence of an airway 
obstruction – tracheostomy may be the treatment of choice.  The surgical 
treatment is followed by a combination of external irradiation and 
chemotherapy. 
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MANAGEMENT OF NECK NODES 
 In the presence of palpable metastatic cervical lymph nodes – Ipsilateral 
modified radical neck dissection type III (functional neck dissection) is the 
treatment of choice for differentiated thyroid cancers and medullary carcinoma. 
Prophylactic central compartment nodal dissection is done for hurtle cell 
carciroma and medullary carcinoma. 
 The presence of metastatic disease to lymph nodes does not alter the 
prognosis for thyroid cancers. 
MANAGEMENT OF LOCALLY ADVANCED THYROID 
CARCINOMA 
 Patients with extra thyroidal extension require en-bloc resection of the 
invaded structures. 
 If tumor is on the anterior thyroid – resection of overlying strap muscles 
is done. This causes minimal morbidity. 
 If tumor is posterior – the margins of resection are either the trachea or 
esophagus.  For well differentiated thyroid cancers, tracheal or esophageal 
resections are not indicated.  If gross involvement of trachea or esophagus is 
present, resection with reconstruction is the appropriate procedure. (5) 
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B. POSTOPERATIVE MANAGEMENT 
1. Iodine 131 Therapy (Radioiodine Therapy) 
 Indications for post operative radioiodine therapy are 
1. All papillary and follicular carcinomas larger than 1.0 to 1.5 cm 
2. Locally invasive well differentiation thyroid cancers 
Postoperative radioiodine therapy reduces recurrence, development of 
distant metastases and causes a improvement in survival (5).  Metastatic 
differentiated thyroid carcinoma can be detected and treated by 131I in 75% 
patients. 
T4 therapy should be discontinued for approximately 6 weeks before 131I 
scanning. Patients should receive T3 during this time to decrease the period of 
hypothyroidism – it is discontinued for 2 weeks to allow TSH levels to rise 
prior to treatment.  Low iodine diet is recommended during this 2 week period. 
Doses for treatment of metastic disease are as follows: 
Screening Dose : 2 mCi of 131I 
Therapeutic Dose : 30-100 mCi in low risk patient 
    100-200 mCi in high risk patient 
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2. Thyroid Hormone 
 The growth of thyroid tumor cells is controlled by TSH and inhibition of 
TSH secretion with levothyroxine decreases recurrence and improves survival 
rates.  All patients with well differentiated thyroid cancer should take thyroxine 
postoperatively. 
 Thyroxine should be administered to ensure that the patient remains 
enthyroid with circulating TSH levels at about 0.1 μU/L in low risk patients or 
less than 0.1 μU/L in high risk patients (14). 
 In patients with anaplastic thyroid carcinoma, medullary carcinoma or 
thyroid lymphoma replacement dose of levothyroxine is given with the aim of 
obtaining a serum TSH level in the normal range. 
3. Thyroglobulin Measurement 
 Thyroglobulin levels should be below 2 ng/ml when patient is taking 
thyroxine and below 5 ng/ml when patient is not taking thyroxine (14).  A high 
thyroglobulin level is highly suggestive of metastatic disease or persistent 
normal thyroid tissue. 
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4. External Beam radiotherapy 
1. It is used to control unresectable, locally invasive or recurrent disease. 
2. It is used to treat metastasis in support bones to decrease the risk of fractures. 
3. It can be used for treatment and control of pain from bony metastases when 
there is minimal or no radio iodine uptake. 
5. Chemotherapy 
 Indications for chemotherapy are: inoperable and 131I resistant tumors 
Adriamycin and Taxol are the most frequently used agents. 
OUTCOME PREDICTION 
 The overall 10 year survival for patients with well differentiated 
papillary thyroid carcinoma ranges between 74% and 93% (5).  Patients with 
follicular cancer have a 10 year survival of 43% to 94% (5). 
For patients with anaplastic thyroid carcinoma, the median survival is 3 to 4 
months from the time of diagnosis (5). 
The 10 year survival for patients with medullary thyroid cancer is 70-80% (4). 
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RECENT LITERATURE 
 Predicting Outcome and directing therapy for papillary thyroid 
carcinoma (10). Kim S et al., concluded in this study that papillary thyroid 
carcinomas in low risk patients had a favourable prognosis regardless of 
treatment.  Older high risk patients had a survival benefit with total 
thyroidectomy and lymph node dissection.  Radioactive iodine did not affect 20 
year survival in any of the risk groups. 
 Predictive factors in mortality and morbidity in patients with 
differentiated thyroid cancer.  The conclusions drawn from this study were.  
The mortality rate is high for those who are 45 years and older.  Patients with 
tumor size less than 4 cm had significantly lower mortality and recurrence.  
Other significant risk factors for death were male sex and follicular thyroid 
cancer (as opposed to papillary thyroid cancer). 
 Haigh PI et al., (8) in their study showed that the extent of 
thyroidectomy is not a major determinant of survival in low or high risk 
papillary thyroid cancer. 
 Another study by Bilimoria KY et al., (4) however, demonstrated that 
total thyroidectomy results in lower recurrence rate and improved survival for 
papillary thyroid cancer ≥ 1 cm compared with lobectomy. 
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 Thus controversy still exists over the extent of surgery for differentiated 
thyroid cancers. 
 rhTSH – aided radioiodine ablation and treatment of differentiated 
thyroid carcinoma (11):  Luster M et al found that rh TSH  aided treatment may 
be preferred in patients who are at greater risk of hypothyroid complications 
from withdrawal of thyroid hormone or are unable to produce sufficient 
endogenous TSH. 
 Shaha AR et al (15) have made the following observations and 
recommendations for management of thyroid cancer.  The incidence of thyroid 
cancer is rapidly increasing.  A large number of incidentalomas are found 
during routine head and neck evaluations.  The diagnostic workup revolves 
around fine needle aspiration biopsy.   Ultrasound guided fine needle aspiration 
biopsy is likely to yield the best results.  Surgical resection offers the best 
treatment choice.  Controversy continues in relation to total versus less than 
total thyroidectomy.  The incidence of complications is inversely proportional 
to the extent of surgery.  The decision regarding the extent of thyroidectomy 
should be based on prognostic factors and risk groups.  Prognostic factors are 
age, grade of tumor, extrathyroidal extension, size, distant metastasis and 
histology.  Nodal metastasis does not alter prognosis.  Based on these 
prognostic factors, thyroid cancers can be divided into low, intermediate and 
high risk groups.  In the high risk group and in selected intermediate risk 
patients, radioactive iodine dosimetry and ablation should be considered after 
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total thyroidectomy.  PET scanning and the use of recombinant TSH have been 
major advances in follow up care for patients with thyroid cancer.  
Thyroglobulin appears to be a very good tumor marker for follow up.  No 
major breakthrough is noted in the management of anaplastic thyroid cancer.  
Identification of RET mutation has been extremely helpful in evaluating the 
family members of the patient with medullary thyroid cancer with strong 
consideration given to total thyroidectomy. 
 Clinicopathological characteristics and longterm outcome in patients 
with distant metastasis from differentiated thyroid cancer (3):  Benbassat. CA 
et al., concluded from their study that complete resection of the thyroid gland at 
diagnosis and high dose adjuvant radioactive iodine are associated with 
improved survival in patients with metastatic DTC. 
 Role of radioactive iodine for adjuvant therapy and treatment of 
metastases (9).  The article by Jonklass J. showed that radioiodine 
administration is a unique and powerful means of treating differentiated thyroid 
cancer because of the ability of thyroid cancer cells to concentrate beta emitting 
radiolabeled iodine.  Several manipulations such as iodine depletion and 
thyroid hormone stimulating hormone elevation are used to enhance uptake of 
radiolabeled iodine by tumor cells.  When radioactive iodine therapy is used in 
patients with residual or metastatic disease it clearly improves outcomes.  It 
decreases recurrence and morality rates in thyroid cancer patients. 
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TECHNIQUE OF TOTAL THYROIDECTOMY 
Preoperative preparation 
 The main aim of preoperative preparation is to make the patient 
euthyroid at operation 
Anesthesia 
 General anesthesia with nitrous oxide and oxygen is usually preferred. 
Position 
 The neck of the patient is extended by placing a pillow below the 
shoulders. 
Technique (2) 
 Incision: A curved incision is made about 2 finger breaths above the 
suprasternal notch extending from the lateral border of one sternomastoid 
muscle to the corresponding point on the other sternomastoid muscle.  Skin and 
superficial fascia are incised.  The playsma is divided at a slightly higher level 
to produce a fine scar.  The upper flap containing skin, subcutaneous tissue and 
platysma is reflected upwards to the level of the thyroid cartilage.  The lower 
flap is reflected downwards to the sternum.  The anterior jugular veins may 
require division between ligatures. 
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Exposure of the goiter 
 The investing layer of the deep fascia is incised vertically in the midline.  
The infrahyoid muscles are retracted.  The veins, which come in the way are 
divided between ligatures.  The anterior surface of the gland covered by 
pretracheal fascia is exposed.  This fascia is incised and a finger is insinuated to 
know the whole extent of the thyroid.  If retraction of the infrahyoid muscles 
does not provide adequate exposure of the gland the infrahyoid strap muscles 
can be divided as high as possible to avoid damage to the Ansa cervicalis. 
Ligature of pedicles 
 The lateral surface of the thyroid lobe is cleared by finger dissection.  
The upper pole of the gland is delivered into the wound.  The superior thyroid 
vessels will be seen forming the vascular pedicle.  These vessels are clamped, 
cut and ligated as close to the gland as possible to avoid injury to the external 
laryngeal nerve.  The middle thyroid vein is the identified by retracting the 
lateral lobe forward.  This vein is ligated and divided.  This step may be done 
before ligation of the superior pole.  The recurrent laryngeal nerve is identified 
all along its course.  The inferior thyroid artery is then identified and ligated in 
continuity taking care not to damage the nerve.  The same procedure is 
performed on the opposite side. 
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Resection of the goitre 
 The thyroid gland is mobilized off the trachea by applying serial 
hemostats to the capsule of the lobe on its posterolateral aspect.  The lobe is 
then sectioned from lateral to medial side, in a plane towards the front of the 
trachea.  The wound is closed in layers.  A suction drain may be kept for a 
period of 24-48 hours. 
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MATERIALS AND METHODS 
 This is a combined retrospective and prospective study of all patients 
with thyroid cancers admitted in the Departments of General Surgery and 
Surgical Oncology at the Government Kilpauk Medical College and Hospital 
and the Government Royapettah Hospital from January, 2005 to July, 2007.  
Patients who had thyroid carcinoma on histopathologic examination were 
included in the study. 
 All the patients with thyroid disease underwent a detailed clinical 
examination and indirect laryngoscopy (done by E.N.T. Surgeons) for 
evaluation of vocal cord status.  All patients with an obvious thyroid swelling 
were subjected to an ultrasound of the neck and a Fine Needle Aspiration 
Cytology (FNAC).  Patients who were symptomatic or had a positive or 
indeterminate FNAC were subjected to surgery.  After surgery, all patients with 
differentiated thyroid cancers received suppressive dose of thyroxine.  The 
patients were then followed up regularly after discharge or till the time of 
death. 
 The relevant information was tabulated and used for analysis.  The 
observations were compared with the current literature on thyroid cancers and 
conclusions were drawn. 
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OBSERVATIONS AND DISCUSSION 
 All patients with thyroid cancer proven by histopathology admitted 
between January, 2005 and July, 2007 were included in the study.  The study 
group consisted of 72 patients.  A proforma was used to record the pertinent 
information about each patient.  This was summarized into a master chart.  The 
statistical inferences drawn are presented below. 
1. Prevalence of the different types of Thyroid Cancer 
The prevalence of the different types of thyroid cancers in the study group is as 
follows: 
Table - 1  
Type of Thyroid Cancer No. of Cases % of Total 
Papillary 62 86.1 
Follicular 1 1.4 
Medullary 6 8.3 
Anaplastic 2 28 
Large cell lymphoma 1 1.4 
Total 72 100 
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Diagram - 1 
 
86.10%
1.40%
8.30%
2.80%
1.40%
Papillary Ca
Follicular
Medullary
Anaplastic
Large cell lymphoma
 
 
Papillary Carcinoma (86.1%) is found to be the commonest type of thyroid 
cancer followed by medullary carcinoma of thyroid (8.3%) 
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2. Sex Distribution 
The sex distribution of thyroid cancers is tabulated below 
Table - 2 
Sex No. of Cases % of Total 
Males 18 25 
Females 54 75 
Total 72 100 
 
Diagram - 2 
25%
75%
Male
Females
 
There is a female preponderance seen in thyroid cancers 
The male: female ratio is 1:3 
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Table - 3 
The sex incidence in different types of thyroid cancers is as follows: 
Males Females Type of 
thyroid 
cancer 
Number 
of cases 
Percentage Number 
of cases 
Percentage 
Total No. 
of cases 
Papillary 16 25.8 46 74.2 62 
Follicular - - 1 100 1 
Medullary 1 16.67 5 83.33 6 
Anaplastic 1 50 1 50 2 
Large cell 
lymphoma 
- - 1 100 1 
Total 18  54  72 
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Diagram - 3 
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Papillary carcinoma is the commonest type of thyroid cancer seen in teeth 
males and females 
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3. Age Distribution 
The age distribution of thyroid cancers is as documented below 
Table - 4 
Age in years Males Females Total 
<10 - - - 
11-20 1 7 8 
21-30 4 19 23 
31-40 1 13 14 
41-50 7 6 13 
51-60 3 7 10 
>60 2 2 4 
 18 54 72 
 
Diagram - 4 
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The peak incidence of thyroid cancers is between 21-30 years of age. 
The peak incidence of thyroid malignancies in males is between 41-50 years of 
age and in females is between 21-30 years of age. The average age of 
presentation of thyroid cancer is 38.3 years. 
The average age of incidence of thyroid cancers in males and females is as 
follows 
Table - 5 
Sex Average Age of Incidence 
Males 44 yrs 
Females 36.7 yrs 
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4. Distribution of patients according to age and peak incidence for the different 
types of thyroid cancers is as follows 
Table - 6 
Type of cancer Age Range 
(in years) 
Average age of 
incidence 
(in years) 
Peak incidence 
(in years) 
Papillary 13-78 36.5 21-30 
Follicular 55 55 51-60 
Medullary 27-60 41.5 31-40 
Anaplastic 60-65 62.5 ≥60 
Large cell 
lymphoma 
55 55 51-60 
 
Papillary & Medullary carcinomas are seen in the younger age group than the 
other types of thyroid cancers 
5. Symptomatology 
 69 cases out of the 72 cases in the study group presented with thyroid 
swelling.  Regional lymph node metastasis was seen in 25 patients and distant 
metastasis in 2 patients.  1 patient had an occult papillary carcinoma (with no 
thyroid swelling). 2 patients with papillary carcinoma who had undergone 
thyroidectomy previously presented during the study period with cervical nodal 
metastasis. 
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The findings noted are tabulated below: 
Table - 7 
Symptoms Papillary Follicular Medullary Anaplastic Large cell 
lymphoma 
Total Percentage
Thyroid 
swelling 
       
MNG 31 - 2 2 1 36 50 
SNT 28 1 4 - - 33 38.9 
Absent 3 - - - - 3 4.2 
Dysphagia 2 2 - 2 - 6 8.3 
Dyspnea 4 - - 2 - 6 8.3 
Hoarseness 2 - - 2 - 4 5.5 
Regional 
lymph 
node 
metastasis 
24 - 1 - - 25 34.7 
Vocal cord 
palsy 
1 - - 2 - 3 4.2 
Distant 
metastasis 
1 - - 1 - 2 2.8 
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6. Treatment of Thyroid Malignancy 
The commonest surgery done for the primary cancer is total 
thyroidectomy. 22 out of 25 (88%) patients with palpable cervical nodes were 
subjected to Modified radical neck dissection on the involved side (ie the side 
with palpable nodes).  Bilateral paratracheal dissection was also done in all 
these cases.  17 patients out of the 47 patients (36%) without regional lymph 
nodes underwent a bilateral paratracheal dissection.  3 patients underwent 
trucut biopsy for histopathological confirmation of diagnosis and were treated 
by non surgical modalities - the patient with papillary carcinoma was treated 
with external beam radiotherapy.  The patients with undifferentiated cancer and 
lymphoma were treated with radiotherapy and chemotherapy. The observations 
are as tabulated below: 
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Table - 8 
Types of surgery Papillary Follicular Medullary Anaplastic Large cell 
lymphoma 
Thyroidectomy      
Total 
thyroidectomy 
39  1 1  
Near total 
thyroidectomy 
2     
Subtotal 
thyroidectomy 
4  1   
Hemithyroidectomy 7  2   
Completion 
thyroidectomy 
9 1 2   
Neck Dissection      
MRND / RND / 
FND 
22     
Paratracheal 
dissection 
17     
Posterolateral neck 
dissection 
2     
Trucut Biopsy 1   1 1 
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Diagram - 6 
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Distribution of patients undergoing thyroidectomies 
Diagram - 7 
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Distribution of patients undergoing Neck dissections 
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All patients with differentiated thyroid cancers were followed postoperatively 
with suppressive doses of thyroxine. The other patients were given replacement 
doses of thyroxine. 
7. Outcomes of thyroid cancer in the study group 
 Life expectancy following surgery could not be determined because of 
the short duration of the study. 2 patients died during the follow up period-both 
with anaplastic carcinoma. 
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CONCLUSION 
1. Incidence of various types of thyroid cancers correlates approximately 
with the world literature except for follicular carcinoma which has a 
lower incidence in the study group. 
Type of carcinoma % In the study group World literature (%) 
Papillary 86.1 80-85 
Follicular 1.4 5-10 
Medullary 8.3 < 10 
Anaplastic 2.8 5 
Lymphoma 1.4 < 2 
 
Papillary carcinoma of thyroid is the commonest thyroid malignancy in the 
study group.  This correlates with the world literature (5).  The incidence of 
follicular carcinoma is lower than the world literature. 
2. Male: Female ratio in the study group is 1:3.  This is comparable to the 
world literature where male: female ratio is 1:2.5 (5) 
3. In the study group, median age at diagnosis for females is 30 years and 
for males is 44 years.  This is comparable to the known literature where 
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median age at diagnosis is earlier in females than in males for both 
papillary and follicular subtypes (5). 
4. Usually 2/3 rd (67%) of patients with differentiated thyroid carcinoma 
have disease localized to thyroid at presentation (5).  In the study group, 
60.3% patients have disease localized to the thyroid. 
5. According to known data, 33-61% of patients with papillary thyroid 
cancer have metastatic cervical lymphadenopathy at diagnosis (5).  In 
this study group, 38.7% patients (ie 24 patients out of 62) with papillary 
thyroid cancers had metastatic cervical lymph nodes at presentation. 
6. 1-2% of patients with papillary thyroid cancer have distant metastasis at 
diagnosis (5).  In the study group 1.6% of patients (ie 1 patient out of 64 
patients) had distant metastasis.  This is associated with a very poor 
prognosis. 
7. The most common symptom at presentation for all thyroid cancers is a 
thyroid swelling.  26.3% of patients presented with symptoms of locally 
advanced disease. 
8. Total thyroidectomy is now advocated for all well differentiated thyroid 
cancers and medullary thyroid cancer. Central compartmental dissection 
is to be done for all medullary thyroid cancers.  Modified Radical Neck 
dissection is recommended only in the presence of metastatic cervical 
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lymph nodes.  In the study group, total thyroidectomy was the 
commonest surgery performed. 22 out of 25 patients (88%) with 
palpable cervical lymph node underwent modified radical neck 
dissection on the involved side. 
9. A combination of radiotherapy and chemotherapy (with adriamycin) is 
the most appropriate therapy for non resectable undifferentiated 
carcinomas (5).  In the study group, one patient with anaplastic 
carcinoma underwent a total thyroidectomy supplemented with 
postoperative radiotherapy and chemotherapy.  The other patient was 
treated with radiotherapy and chemotherapy alone. 
10. TSH suppressive doses of levothyroxine is recommended for all patients 
with papillary and follicular thyroid cancers.  This was followed for all 
patients in the study group with differentiated thyroid cancers.  The goal 
of this therapy is serum TSH concentration of 0.1 mU/L or less. 
11. Life expectancy of patients following surgery could not be ascertained 
due to the short duration of the study.  2 patients died during the follow 
up period – both were diagnosed to have anaplastic carcinoma of 
thyroid. 
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PROFORMA 
 
 
Name:  Age:  Sex: 
 
Inpatient No.:     Ward: 
 
 
I PRESENTING FEATURES 
 
1. Swelling    : Side 
      Duration 
      Progress 
      Any sudden change in size 
 
2. Pressure effects   : Dysphagia 
      Dyspnoea 
 
3. Pain 
 
4. Hoarseness of Voice 
 
5. Toxic symptoms 
 
6. Loss of Weight 
 
7. Hypo or Hyper Thyroid Symptoms 
 
8. Any other neck Swelling 
 
II. H/O PREVIOUS SURGERY / IRRADIATION 
 
III. MENSTRUAL AND OBSTETRIC HISTORY 
 
IV FAMILY H/O. DEATH FROM THYROID MALIGNANCY 
 
 
 Pheochromocytoma 
 
 Diabetes 
  
 Hypertension 
 
 Tuberculosis 
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V. GEN. EXAMINATION: 
 
Pulse 
 BP 
 Anaemia 
 
 
VI. EXAMINATION OF LUMP 
 
1. Site 
2. Size 
3. Shape 
4. Surface 
5. Extent 
6. Margins 
7. Skin over the swelling 
8. Consistency 
9. Movement with Deglutition 
10. Intrinsic Mobility 
11. Fixity 
12. Tracheal Position 
13. Carotids 
14. Mediastinal Extension 
15. Auscultation for Bruit 
16. Neck Nodes 
17. Bone 
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VII. EXAM OF OTHER SYSTEMS 
 
VIII. Laboratory   Post operative complication  
 Chest X-Ray   Hemorrhage 
 X-Ray Neck   Hypoclacemia 
 IDL    Rec. Laryngeal Nerve Palsy 
 Thyroid scan   Respiratory Obstruction 
 FNAC    Follow up 
 USG    After every 3 months 
 
Treatment 
Surgery 
Node Dissection 
Radiotherapy 
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MASTER CHART 
S.No. Name Age Sex IP No. Thyroid 
Swelling 
MNG/ 
SNT/None 
Dysp-
nea 
Dysph-
agia 
Hoarse-
ness 
Regional 
Lymph 
Node 
metastasis 
Vocal 
cord 
palsy 
Distant 
Meta-
stasis 
FNAC Treatment Histo-
pathology 
Out-
come 
1 Girija 35 F 3529/05 MNG - - - - - - Papillary Ca Subtotal 
thyroidectomy 
Medullary Ca alive 
2 Ramani 31 F 9896/05 R SNT + + + - + - Papillary Ca Total 
thyroidectomy 
Papillary Ca alive 
3 Sathyabama 30 F 13791/05 MNG - - - - - - Collid goiter Subtotal 
thyroidectomy 
Micropapillary 
Ca 
alive 
4 Rani 24 F 15437/05 MNG + - + - - - Cystic 
macrophages 
& 
Inflammatory 
cells in 
fibrinous 
background 
Subtotal 
thyroidectomy with 
(L) Paratracheal 
dissection 
Papillary Ca alive 
5 Kullammal 40 F 4612/05  R SNT - - - - - - To rule out 
neoplasm 
R 
Hemithyroidectomy 
Medullary Ca alive 
6 Govindammal 27 F 19758/05 None - - - + - - Occult 
papillary Ca 
Total 
thyroidectomy with 
R FND 
Occult 
papillary Ca 
alive 
7 Radha 26 F 5057/05 MNG + + - + - - Adenomatous 
goiter 
R 
Hemithyroidectomy 
with  MRND 
Papillary Ca 
with 
Hashimoto’s 
thyroiditis 
alive 
8 Sarasu 58 F 172508/05 R SNT + - - - - - To rule out 
follicular 
neoplasm 
 R 
Hemithyroidectomy 
Papillary Ca alive 
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9 Pavuru 55 F 23826/05 R SNT - - - - - - To rule out 
follicular 
neoplasm 
R 
Hemithyroidectom
y followed by 
completion 
thyroidectomy 
Minimally 
invasive 
follicular 
Ca 
alive 
10 Vijaya 35 F 24879/05 MNG - - - - - - Nodular goiter Near total 
thyroidectomy 
Papillary 
Ca 
alive 
11 Indira 27 F 24710/05 MNG - - - - - - Hyperplastic 
nodule in 
goiter 
Subtotal 
thyroidectomy 
Papillary 
Ca (solid 
variant) 
alive 
12 Manonmani 20 F 25393/05 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
Papillary 
Ca (solid 
variant) 
alive 
13 Rajeshwari 30 F 27383/05 MNG - - - + - - Papillary Ca Total 
thyroidectomy 
with B/L 
paratracheal 
dissection 
Papillary 
Ca 
alive 
14 Sankala 30 F 32783/05 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
Papillary 
Ca 
(encapsulat
ed variant) 
alive 
15 Tamilselvi 25 F 798763/05 L SNT - - - + - - Papillary Ca Total 
thyroidectomy 
with B/L RND 
Papillary 
Ca 
(columnar 
type) 
alive 
16 Ravi 45 F 8008791/05 MNG - - - - - - Papillary Ca Total 
thyroidectomy B/L 
paratracheal 
dissection 
Papillary 
Ca 
(follicular 
variant) 
alive 
17 Govindammal 60 F 804736/05 MNG 
(with 
ovarian 
tumor, with 
skin 
infiltration) 
- - - + - - Papillary Ca Trucut Biopsy 
Radiotherapy 
Papillary 
Ca with 
skin 
deposits 
alive 
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18 Ganesan  50 M 835408/05 MNG - - - + - - Papillary Ca Total 
thyroidectomy 
with L MRND 
Papillary Ca alive 
19 Ganesan 50 M 805478/05 R SNT - - - + - - Papillary Ca Total 
thyroidectomy 
with R FND 
Papillary Ca alive 
20 Najitha Banu 20 F 805174/05 R SNT - - - + - - Papillary Ca Total 
thyroidectomy 
with R 
posterolateral 
dissection 
Papillary Ca alive 
21 Benazir 22 F 810201/05 R SNT - - - + - - Papillary Ca Completion 
thyroidectomy 
with R MRND 
Papillary Ca alive 
22 Farhana 27 F 814461/05 L SNT - - - + - - Nodular goiter 1st  L 
hemithyroidectom
y followed by 
completion 
thyroidectomy 
with L FND 
Medullary Ca alive 
23 Kasthuri 17 F 813641/05 (L) 
SNT 
- - - - - - Papillary Ca Completion 
thyroidectomy 
with (L) 
Paratracheal 
dissection 
Papillary Ca alive 
24 Ekambaram 78 M 812154/05 MNG - - - + - - Papillary Ca Total 
thyroidectomy 
with B/L FND 
Papillary Ca alive 
25 Jaya 28 F 816621/05 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
Papillary Ca 
with 
Hashimoto’s 
thyroiditis 
alive 
26 Meena 58 F 816907/05 (R) 
SNT 
- - - - - - Papillary Ca Total 
thyroidectomy 
with (R) 
paratracheal 
dissection 
Papillary Ca alive 
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27 Kanniappan 60 M 819157/05 MNG + + + - + - Anaplastic Ca Trucut Biopsy 
Radiotherapy and 
Chemotherapy 
Anaplastic Ca death 
28 Poongothai 35 F 820595/05 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
Papillary Ca alive 
29 Kamatchi 47 F 823434/05 (L) SNT - - - - - - Papillary Ca Completion 
thyroidectomy 
Papillary Ca alive 
30 Santhikala 29 F 823582/05 MNG - - - + - - Papillary Ca Total 
thyroidectomy  
with (R) FND 
Papillary Ca alive 
31 Govindammal 27 F 824409 (R) SNT - - - + - - Papillary Ca Total 
thyroidectomy with 
B/L FND 
Papillary Ca alive 
32 Selvi 26 F 824892 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
Papillary Ca 
(follicular 
variant) 
 
33 Kamala 37 F 8361/06 MNG - - - + - - Papillary Ca Total 
thyroidectomy with 
(L) FND 
Papillary Ca alive 
34 Umamaheswari 20 F 14307/06 MNG - - - - - - Goitrous lesion Total 
thyroidectomy 
Papillary Ca 
(follicular 
variant) 
alive 
35 Murugan 47 M 17173/06 (L) SNT - - - - - - Nodular goitre (L) 
Hemithyroidectomy 
Medullary Ca alive 
36 Rasool 22 M 183933/06 (L) SNT - - - - - - Goitre (L) 
hemithyroidectomy 
Papillary Ca 
(follicular 
variant) 
alive 
37 Raaji 46 F 20010/06 (R) SNT - - - - - - Cystic change 
in colloid goitre 
(R) 
hemithyroidectomy 
Papillary Ca 
with evolving 
thyroiditis 
alive 
38 Tirumaran 26 M 32160/06 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
Papillary Ca alive 
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39 Arulmozhi 16 F 34426/06 (R) SNT - - - - - - Nodular goitre (R) 
Hemithyroidectomy 
Papillary Ca 
(follicular 
variant) 
alive 
40 Nirmala 32 F 837659/06 (L) SNT - - - - - - Notular goitre (L) 
Hemithyroidectomy 
Papillary Ca alive 
41 Saraswathy 40 F 837297/06 (L) SNT - - - - - - Papillary Ca Total 
thyroidectomy with 
B/L paratracheal 
dissection 
Papillary Ca alive 
42 Adhilakshmi 38 F 840389/06 (R) SNT - - - + - - Papillary Ca Total 
thyroidectomy with 
(R) FND 
Papillary Ca alive 
43 Kanniappan 24 M 841139/06 (L) SNT - - - + - - Papillary Ca Total 
thyroidectomy with 
(L) FND 
Papillary Ca alive 
44 Rani 48 F 841036/06 (L) SNT - - - + - - Papillary Ca Total 
thyroidectomy with 
(L) FND 
Papillary Ca alive 
45 Guruswamy 58 M 845966/06 MNG - - - + - - Papillary Ca Total 
thyroidectomy with 
(R) RND 
Papillary Ca alive 
46 Pitchandi 32 M 844370/06 (R) SNT - - - - - - Nodular goitre (R) 
Hemithyroidectomy 
followed by 
completion 
thyroidectomy with 
B/L paratracheal 
dissection 
Papillary Ca alive 
47 Latha 39 F 847685/06 (R) SNT - - - + - - Papillary Ca Total 
thyroidectomy with 
(R) FND 
Papillary Ca alive 
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48 Irulayammal 65 F 850903/06 MNG + + + - + + (Iliac 
Bone 
Mass) 
Anaplastic Ca Total 
thyroidectomy 
Anaplastic Ca 
(spindle cell 
variant) 
death 
49 Lalitha 60 F 852794/06 (L) SNT - - - + - - Nodular goitre Completion 
thyroidectomy 
with B/L 
paratracheal 
dissection 
Medullary Ca alive 
50 Kristaiah 42 M 850179/06 (R) SNT - - - + - - Papillary Ca Total 
thyroidectomy 
with B/L FND 
Papillary Ca alive 
51 Padma 55 F 854033/06 MNG - - - - - - To rule out 
neoplasm 
Trucut biopsy 
chemotherapy 
radiotherapy 
Large cell 
lymphoma 
alive 
52 Suji 27 F 860123/06 (R) SNT - - - - - - Papillary Ca Completion 
thyroidectomy 
with B/L 
paratracheal 
dissection 
Papillary Ca alive 
53 Leonard 68 M 859679/06 MNG - - - + - - Papillary Ca Total 
thyroidectomy 
with (R) RND 
with 
deltopctoral 
flap 
Papillary Ca alive 
54 Kannamma 45 F 3702/07 (R) SNT - - - - - - Colloid nodule Total 
thyroidectomy 
Micropapillary 
Ca 
alive 
55 Janaki 28 F 7341/07 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
Papillary Ca alive 
56 Kondammal 48 F 6769/07 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
Papillary Ca alive 
57 Sabarathinam 13 M 8859/07 MNG - - - - - - Dyshormonogenetic 
goitre 
Total 
thyroidectomy 
Papillary Ca alive 
58 Geetha 26 F 11452/07 (R) SNT - - - - - - Nodular goitre Near total 
thyroidectomy 
Papillary Ca alive 
59 Girija 40 F 13289/07 MNG - - - - - - Follicular 
Neoplasm 
Total 
thyroidectomy 
Medullary Ca alive 
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60 Susheela 40 F 862281/07 MNG - - - + - - Papillary Ca Total 
thyroidectomy 
with (L) FND 
Papillary Ca alive 
61 Suresh 30 M 863388/07 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
with (R) 
paratracheal 
dissection 
Micro 
Papillary Ca 
alive 
62 Shyamala 20 F 868272/07 MNG - - - - - - Papillary Ca Subtotal 
thyroidectomy 
Papillary Ca alive 
63 Vellaisamy 45 M 531892/07 (R) SNT - - - - - - Papillary Ca Total 
thyroidectomy 
with B/L 
paratracheal 
dissection 
Papillary Ca alive 
64 Hussaini Basha 43 M 8675491/07 (R) SNT - - - - - - Papillary Ca Completion 
thyroidectomy 
with B/L 
paratracheal 
dissection 
Papillary Ca alive 
65 Umaiyal 27 F 868820/07 MNG - - - - - - Papillary Ca Total 
thyroidectomy 
with B/L 
paratracheal 
dissection 
Papillary Ca alive 
66 Gnanaprakasam 60 M 868585/07 MNG 
(post 
radiothe-
rapy) 
- - - - - - Papillary Ca Total 
thyroidectomy 
with B/L 
paratracheal 
dissection 
Papillary Ca alive 
67 Lakshmi 57 F 870638/07 MNG - - - + - - Papillary Ca Total 
thyroidectomy 
with (L) FND 
Micropapillary 
Ca 
alive 
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68 Kasthuri 64 F 872081/07 None - - - + (nodal 
recurrence) 
- - Papillary Ca Completion (L) 
thyroidectomy 
with type II (R) 
MRND 
followed by 
split skin graft 
Papillary 
Ca 
alive 
69 Latha 39 F 871067/07 None - -  + (nodal 
recurrence) 
- - Papillary Ca (R) MRND 
Type II 
Papillary 
Ca 
alive 
70 Ganga 38 F 873984/07 (L) SNT - - - - - - Papillary Ca Completion (L) 
thyroidectomy 
Papillary 
Ca 
alive 
71 Lavanya 22 F 872086/07 (R) SNT - - - - - - Papillary Ca Total 
thyroidectomy 
with B/L 
paratracheal 
dissection 
Papillary 
Ca 
alive 
72 Thilagavathy 48 F 873839/07 MNG - - - - - + (sacral 
metastases) 
Papillary Ca Total 
thyroidectomy 
with B/L 
paratracheal 
dissection 
Papillary 
Ca 
alive 
 
FND  : Functional Neck Dissection   RND  : Radical Neck Dissection 
MRND : Modified Radical Neck Dissection  SNT  : Solitary nodule of thyroid 
MNG  : Multinodular Goitre    R & L : Right and Left 
FNAC : Fine Needle Aspiration Cytology 
